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Women worldwide are two to three times more likely to suffer from depression in their
lifetime than are men. Female risk for depressive symptoms is particularly high during
the reproductive years between menarche and menopause. The term “Reproductive
Mood Disorders” refers to depressive disorders triggered by hormonal fluctuations during
reproductive transitions including the perimenarchal phase, the pre-menstrual phase,
pregnancy, the peripartum period and the perimenopausal transition.
Here we focus on reproductive mood disorders manifesting in adult life. We propose
a research agenda that draws together several reproductive mood disorders and
investigates which genetic, endocrinological, neural, and psychosocial factors can
explain depressive symptoms during phases of hormonal transitions in women. Based
on current research it is assumed that some women experience an increased sensitivity
to not only fluctuations in reproductive steroids (estrogen and progesterone), but
also stress-related steroids. We integrate both dynamics into the concept of “steroid
hormone sensitivity,” expanding on the concept of “reproductive hormone sensitivity.” We
suggest that a differential response of the stress steroid system including corticosteroids,
neurosteroids, like allopregnanolone and the GABA-A Receptor complex, as well as a
differential (epi)genetic risk in serotonergic and GABAergic signaling, are moderators or
mediators between changes in the reproductive steroid system and the physiological,
affective, and cognitive outcomes manifesting in reproductive mood disorders. We point
to the lack of research on the role of psychosocial factors in increasing a woman’s stress
level and at some point also the sensitivity of her stress steroid system within the etiology
of Reproductive Mood Disorders.
Drawing together the evidence on various reproductive mood disorders we seek to
present a basis for the development of more effective pharmacological, social, and
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psychological treatment interventions and prevention strategies for women susceptible
to these disorders. This could pave the way for new research as well as medical and
psychological teaching and practice- such as a new type of Practice for Gynecological
Psychoneuroendocrinology- with the aim of working on and ultimately offering more
integrative forms of support not yet available to women suffering from depression
during hormonal transitions. In medical history women have been left alone with this
integrative challenge.
Keywords: depression, stress, allopregnanolone, GABARA receptor, premenstrual, perinatal, perimenopausal,
peripartal
INTRODUCTION
Women all over the world are two to three times more likely
to suffer from depression in their lifetime compared to men
(1). This risk is particularly high during the reproductive years
between menarche and menopause. This suggests that mood
disorders triggered by changes in reproductive steroid hormones
during reproductive transitions- including the perimenarchal
phase with first-onset depression (2–4), the menstrual cycle,
pregnancy, the peripartum period and the menopause transition-
may account for an important proportion of this increased
risk. Indeed, an estimated 13–19% of reproductive-aged women
experience clinically significant premenstrual mood disturbance
each month (5, 6); 25% experience significant mood symptoms
during or following pregnancy (7) and approximately 45–68% of
women experience clinically significant mood symptoms during
the menopausal transition (8). While each disorder is unique,
it is also believed that increased sensitivity to fluctuations in
reproductive steroid hormone levels represent an underlying
etiologic process common to all three reproductive phases (9).
For this reason, this cluster of mood disorders occurring in the
context of reproductive transitions are frequently referred to as
“Reproductive Mood Disorders” (RMDs) in academic circles and
will be the focus of this review.
We will begin by briefly introducing the key neuroendocrine
factors featured in all RMDs and will then proceed in
the following sections with a more in depth look at three
RMDs occurring in adult life: premenstrual dysphoric disorder
(PMDD), peripartum depression (PPD), and perimenopausal
depression (PMD). We will also describe reproductive steroid
hormone environments that characterize each reproductive
transition, and the evidence for the involvement of increased
sensitivity to reproductive steroid hormones in the etiology of
each disorder, as well as the role of stress-relevant mechanisms
like the hypothalamic pituitary adrenal (HPA) axis, neurosteroids
and GABARAR receptors. Furthermore, we end each section
with genetic considerations specific to each RMD as well as
neuroimaging findings. As a final step, we seek to draw together
the evidence from the various RMDs to outline a common
etiology, while also discussing potential differences between
them. Building on earlier initiatives to discuss a shared etiology
between the RMDs [e.g., (10–12)], we expand the previously
established concept of reproductive steroid hormone sensitivity
toward the concept of “steroid hormone sensitivity,” in order
to also integrate the contributions of stress-related steroid
hormones and the neurosteroid allopregnanolone (ALLO) at the
GABARAR receptor, a central switch between the reproductive
hormonal system and the HPA Axis. We argue that women
suffering from RMDs not only have an abnormal reaction to
normal reproductive steroid hormone changes, but also an
abnormal reaction to normal stress steroid hormonemechanisms
including ALLO signaling. Psychosocial factors will briefly be
discussed as a pivotal compound in the role of stress sensitivity
in these disorders. Taken together, our perspective on RMDs
is conceptualized with the ultimate goal of informing their
improved diagnosis and treatment as well as improving the early
identification of women who are at the highest risk of RMDs to
enable prevention.
KEY NEUROENDOCRINE FACTORS IN
REPRODUCTIVE MOOD DISORDERS
Sex differentiation in the prevalence of mood disorders begins
with puberty (13). Before adolescence, the rates of depression
are similar in girls and boys or even slightly higher in boys
(12). However, after menarche, a sharp rise in the prevalence
of mood disorders and suicidal behaviors in women can be
observed (14, 15). Although perimenarchalmood disorders could
clearly be considered a RMD, only limited research is available on
the underlying psychoneuroendocrinological mechanisms [see
for instance Smith (16)]. However, as will be presented in the
Neuroimaging Section The Role of Serotonergic Function in
RMDs: Possible Direct and Interactive Pathways below, the
findings from this strand of research clearly distinguish pubertal
depression from the other adult RMDs. Therefore, we here focus
on RMDs manifesting in adult life.
Sensitivity to Changes in Reproductive
Steroids
Reproductive steroid hormones including estrogens,
progesterone and androgens are regulated by the hypothalamic-
pituitary-gonadal (HPG) axis. Briefly, as the initial part of the
HPG axis, the hypothalamus releases gonadotropin-releasing
hormone (GnRH), which stimulates the anterior pituitary to
produce and secrete the gonadotropins- luteinizing hormone
(LH) and follicle-stimulating hormone (FSH). LH passes the
bloodstream and stimulates the release of reproductive steroid
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hormones from the gonads followed by a negative feedback
loop, as illustrated in Figure 1. The HPG axis not only regulates
reproductive function, but also other physiological functioning,
and influences emotion and cognition [as e.g., reviewed in
Gurvich et al. (17)].
The marked increase in mood symptoms during times
of reproductive transitions suggests that common underlying
reproductive steroid hormone-based mechanisms influence
mood symptoms in women. The role of reproductive steroid
hormones in regulating the switch into dysfunctional affective
states in a susceptible group of women has been well-
established by studies showing abnormal symptomatic responses
to experimental steroid hormone manipulations in those with
PMDD (18), peripartum depression (19), and perimenopausal
depression (20), however, the source of this susceptibility remains
unknown. After nearly two decades of research devoted to
clarifying the etiology of RMDs, there is compelling evidence
that these disorders are not characterized by absolute levels in
reproductive steroid hormones but result from an increased
sensitivity to changes in reproductive steroid hormones instead
[see for instance (10, 11, 19–22)]. Therefore, research on RMDs
moves more and more toward a focus on understanding affective
responses to changes in reproductive steroid hormone levels and
the underlying neuroendocrinological and genetic mechanisms
underlying these responses (23). Also, the ratio between the
reproductive steroid hormones estrogen (E2) and progesterone
(P4) has been shown to be crucial in the development of
psychiatric disorders (24).
Sensitivity to Changes in Stress-Related
Steroid Hormones, Neurosteroids, and the
GABAA Receptor Complex
Psychosocial stress is positively associated with the development
and severity of mood disturbances during all phases of
reproductive transition (25–29). In line with this, there is
consistent research showing dysregulations of the hypothalamic-
pituitary-adrenal (HPA) axis in depressive disorders. The effector
hormones of the HPA axis (most prominently cortisol) act
on glucocorticoid- and mineralocorticoid receptors in the
central nervous system and provide negative feedback to further
regulate HPA axis activation [(30); also see Figure 1]. Overall, a
hyperexcitable HPA axis (for instance as a result of significant
early life stress or trauma) has been found to be a common feature
of depression (31, 32).
The γ-aminobutyric acid (GABA) system plays a critical role
in inhibiting the HPA axis at the level of the paraventricular
nucleus (PVN) of the hypothalamus, with GABA as the dominant
inhibitory neurotransmitter (33–35). Neuroactive steroids (NAS)
are metabolites of cholesterol or steroidal precursors that
constitute potent and rapid allosteric modulators of the GABARA
Rreceptor (36). Among them, a neuroactive P4 metabolite, the
neurosteroid 3α-OH-5αβ-pregnan-20-one, or allopregnanolone
(ALLO) is of particular interest in this context (37). ALLO acts
as a positive allosteric modulator of the GABARA Rreceptor
with potent anxiolytic and tranquilizing effects. Animal research
demonstrates an HPA axis-dampening effect of ALLO: ALLO
administration in rats attenuated stress-induced release of
adrenocorticotropic hormone (ACTH) and cortisol; ALLO
also attenuates the stimulated release of the corticotropin-
releasing hormone (CRH) and prevents hypothalamic CRH gene
expression in adrenalectomized rodents [reviewed in Girdler
and Klatzkin (38)].
During the fetal and infant period, important changes in
gene expression related to intracellular chloride concentration
resulting in altered GABAergic tone have been observed. Change
in gene expression affecting these mechanisms seems to occur
for some women, but not all and it can be argued that
this can influence a woman’s risk for RMDs (37). During
early development, GABA is depolarizing and mostly excitatory
due to high [Cl−]. Here it plays a key role by regulating a
number of processes including the migration, morphological
maturation, and differentiation of neurons (39). GABA mediates
Cl(-)dependent inhibitory postsynaptic potentials and alterations
in these mechanisms e.g., due to epigenetic changes due to
excessive stress as described below are related to GABA’s potential
implication in the pathogenesis of disorders, RMDs (37).
Apart from such alterations in GABA-activated CL- channels,
another aspect that is relevant to a better understanding of
a potential mechanism sensitizing some women for RMDs is
that certain stem cells continue to be excitatory in adulthood.
In relation to this aspect of stem cells it can be said that
cognitive functions in adults are modulated by hippocampal
neurogenesis which in adult humans occurs exclusively on the
level of the dentate gyrus (40). The only product of hippocampal
neurogenesis are granule cells as the principal excitatory neurons
of the dentate gyrus (41). They provide excitatory input to the
pyramidal cells of CA3 (42). The precursor cells from which
adult neurogenesis originates receive synaptic input from various
other brain regions including dopaminergic fibers from the
ventral tegmental area, serotonergic projections from the raphe
nuclei, acetylcholinergic input from the septum, and GABAergic
connections from local interneurons (43, 44).
It has been argued that genetic or epigenetic modifications of
the GABARA Rreceptor may contribute to a woman’s sensitivity
to ALLO and, in turn, her risk for mood disturbances in response
to reproductive steroid hormone fluctuations. For instance,
stress in childhood or puberty has been argued to modify the
expression of the αR4Rβδ GABARA Rreceptor and plasticity on
mood and cognition in the face of stress (45). This particular
receptor subunit combination is sensitive for ALLO. Further, the
biosynthesis of ALLO has been argued to be affected by excessive
stress, which in turn compromises cognitive and affective
functioning (46). As Locci and Pinna (46) emphasize, stress-
induced down-regulation of ALLO biosynthesis and changes
in the GABARA Rreceptor have been related to disorders
like posttraumatic stress disorder (PTSD) and depression. On
another note, lower serum ALLO levels were found to be
associated with higher serotonergic binding in the prefrontal
cortex regulating higher cognitive functions and top-down
regulation of emotions, while higher ALLO levels were associated
with lower alertness (47). Sundstrom Poromaa et al. suggest
that this could explain the higher well-being in the follicular
phase of the menstrual cycle. Further, sensitivity (and resulting
affective vulnerability) might be related to epigenetic changes in
genes determining serotonergic functioning (48). However, there
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FIGURE 1 | Neuroendocrine modulation of reproductive mood disorders.
is no scientific evidence yet, that abnormalities in serotonergic
signaling in depressive responses (49) apply to women suffering
from RMDs.
In sum, it is theoretically possible that increased mood
sensitivity to ALLO fluctuation (caused by fluctuations
in reproductive steroid hormones), manifesting as altered
GABAergic tone, would have important consequences for
mood outcomes in the face of stress. As such, dysregulation
in the stress steroid system is considered in the current
manuscript as a potential player in the RMDs, perhaps
mediating the relationship between reproductive steroid
hormone fluctuation as well as subsequent ALLO fluctuation and
mood disturbance in a subset of women. Very recently,
a comprehensive review on the mechanisms between
GABAergic dysfunction and the HPA axis in the context
of depression has been provided (37). However, as it is
noted in this review, most of the presented studies have
employed male subjects only, and the findings may not be
translatable to the female sex. Given the sex differences in
stress reactivity (50), behavior (51), and a potential differential
in the GABARARRsR Rexpression linked to reproductive
steroid hormones (52), our review focuses on findings from
female subjects.
Concerning the role of ALLO in these mechanisms, at this
point, it could be helpful to clearly separate out two issues:
First, paradoxical effects of (normal levels of) ALLO due to a
epigenetic modification of αR4Rβδ GABAR and, and second,
compromised ability to synthesize ALLO (i.e., low ALLO levels)
due to epigenetic modification concerning 3a-HSD and other
enzymes needed to synthesize ALLO from P4. They are likely to
represent two separate issues, since the first is about sensitivity
of the system to normal ALLO changes and the latter is about
deficits in levels of ALLO. As will be outlined below, the RMDs
described in this manuscript differ in the availability of studies
demonstrating the former vs. the latter. In sum, the role of
the epigenetically modified GABARAR receptor composition for
the activation of the receptor by neurosteroids needs further
elucidation in order to better understand RMDs.
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Interactions Between the HPA and the HPG
Axes: The Central Role of GABAergic
Mechanisms
A link between HPA axis activation and HPG axis suppression
has long been established via a suppression of GnRH signaling
to the pituitary and corresponding decrease in FSH and LH
dampening gonadal activity (53). In depressed females (as well
as males) HPA axis activity is inversely related to HPG axis
activity (31). Based on this, a bi-directional relationship between
the experience of stress and activation of the HPG axis has
been suggested: Variability in sex steroids has been related to
stress vulnerability and perimenstrual psychiatric risk (24, 54),
impaired affective adjustment during the peripartum period (55,
56) and perimenopausal depressive symptoms (20).
At the level of the central nervous system, we consider
GABAergic mechanisms as mediators between the HPA and
HPG axes in order to advance our understanding of RMDs. The
GABAergic Deficit Hypothesis of Major Depression posits that
defects in GABAergic neural inhibition can contribute to the
etiology of depressive symptoms and that future antidepressant
therapies could be improved by focusing on the restoration
of GABAergic neurotransmission (57, 58). For comprehensive
reviews of the role of the GABARA RReceptor, the relevant
subunits inmood disorders in the aftermath of stress as well as the
role of ALLO and allotetrahydrodeoxycorticosterone (THDOC)
in this please see the work of Maguire [e.g., (37)] as well as Locci
and Pinna (46).
Both, the HPA and the HPG axes are regulated by GABAergic
transmission at the level of CRH and gonadotropin-releasing
hormone (GnRH) neurons. Higher neurosteroid sensitivity has
been found in GABARA RRs incorporating the δ subunit.
Therefore, stress-derived neurosteroids at GABARA Rreceptors
containing δ subunits have been hypothesized to regulate the
cross-talk between the HPA and the HPG (59). As suggested
from the research above, fluctuations in P4, and subsequent
fluctuations in ALLO could be involved in both HPA and the
HPG axes functioning. However, evidence on the role of ALLO
at central GABARAR receptors, their interplay between the HPA
and the HPG axes and the genesis of RMDs is very limited,
because ALLO mechanisms cannot be measured in the living
human brain. Based on the available data, it can be hypothesized
that women susceptible to RMDs show higher sensitivity to stress
during phases of reproductive steroid hormone variability. This
sensitivity corresponds to altered ALLO-dependent functioning
at the GABARAR receptor in the PVN (see Figure 1). In fact,
there is evidence of a shift in somatic GABA currents (ERGABAR)
in parvocellular neurons in the PVN after chronic early life
stress (60). In sum, chronic stress seems to lead to compromised
GABAergic control of the HPA axis.
Neuroimaging Findings of Reproductive
Mood Disorders
Although much of the literature on the neurobiology of
MDD, which did not make a distinction between men and
women, may still provide valuable insight for RMDs, there
are very few functional brain imaging in fact comparing
dysfunctional neuronal networks in depressed men and women
[e.g., (61)]. Pubertal depression that may manifest as first-
onset depression in the perimenarchal phase was found to
produce neuroimaging results that significantly differ from
the adult Reproductive Mood disorders (PMDD, PPD, PMD)
and are more akin to activation patterns observed in Major
Depressive Disorder (MDD) (62). The identification of a female
depression biotype, as well as differences between female mood
disorders across the reproductive cycle can provide essential
insights concerning their potential respective treatment. The
sub-sections of this article that portray each of these disorders
also include a section reviewing the neuroimaging findings
for the specific reproductive mood disorder manifesting in
adult life.
The Role of Serotonergic Function in
RMDs: Possible Direct and Interactive
Pathways
Altered serotonergic function has also been observed among
women with RMDs, and therefore these mechanisms should
be considered when building theoretical and empirical models
of RMD. Deficits in serotonergic function are observed across
RMDs [as reviewed in Schiller et al. (63)], and pharmacologic
fMRI studies have demonstrated that estrogen and progestin
administration (vs. placebo) cause increased 5-HT2A binding in
brain areas critically involved in emotion regulation, including
the anterior cingulate cortex, dorsolateral prefrontal cortex, and
lateral orbitofrontal cortex (64). The interactions between sex
hormones and the serotonergic system in both healthy women
and those with RMDs are extensively reviewed elsewhere [e.g.,
(63, 65)]. In later sections on various adult reproductive mood
disorders, we will discuss both serotonergic abnormalities and
potential interactions with the GABAergic system as they relate
to specific RMDs.
It could also be the case that the serotonergic and GABAergic
systems interact to cause RMD symptoms (66). As reviewed
by Birzniece et al. (66), a clear interaction between the
GABAergic and the serotonergic systems has been described
in the hippocampus. In this particular area of the brain
serotonin neurons have been found to frequently end at
inhibitory GABAergic interneurons (67). In the context of
the relationship between the GABAergic and the serotonergic
system in reproductive mood disorders (discussed in more detail
below) there have been findings that in vivo administration
of low doses of a 5HT1A receptor agonist with anxiolytic
effects enhances GABA stimulated ClP− Puptake in cortico-
hippocampal synaptoneurosomes (68). More experimental
studies are needed to determine the relevance of these
interactive mechanisms in the regulation of behavior and
RMD symptoms. In this paper, we retain a primary focus
on the GABA/ALLO system while acknowledging the
importance of the serotonin system in RMDs, as there is
a possibility that there are important interactions between
the GABAergic and serotonin systems in the etiology
of RMDs.
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PREMENSTRUAL MOOD DISORDERS
Premenstrual mood disorders include premenstrual syndrome
(PMS), PMDD, and premenstrual exacerbation (PME) of
ongoing mood disorder (69). It is estimated that 13–19%
of naturally cycling women experience clinically significant
emotional PMS symptoms (5, 6) and that about 5% meet
diagnostic criteria for PMDD (70), a severe form of PMS recently
formalized as a new diagnosis in the DSM-5 (71). PMDD
is characterized by the recurrent luteal phase emergence of
clinically significant affective symptoms that become minimal or
absent after the onset of menstruation (72–74). This “on-off”
pattern in which symptoms are fully confined to the luteal phase
has been emphasized as a critical diagnostic feature for selecting
“pure” PMS/PMDD (i.e., without comorbidities) in research
studies; however, there may be important variability in the exact
timing of the onset and resolution of symptoms in PMDD
and related syndromes (75). With respect to PME prevalence,
prospective data from epidemiologic studies indicate that
roughly 60% of women with depressive disorders demonstrate
clinically significant PME of at least one depressive symptoms
(76). Therefore, premenstrual mood disorders affect a large
portion of women. While PMDD was not coded for in the ICD-
10, PMDD is new in ICD-11 where it is put under gynecologic
disorders, but is cross-listed as a depressive disorder. This might
cause confusion, since there is no evidence for a gynecologic
pathology in PMDD. ICD-11 will not come into effect until the
year 2022, which means that it is currently not used in most
places. At themoment there is an ICD-11 Browser made available
by the World Health Organization (WHO), where these new
categories can be found (World Health Organization, ICD-11
Browser, Version 2019).
Sensitivity to Changes in Reproductive
Steroids in PMS/PMDD
The reproductive steroid hormones E2 and P4 change in a
predictable fashion across the prototypical 4-week menstrual
cycle. In the first week, which starts withmenstrual bleeding, both
E2 and P4 are low and stable, followed by a large abrupt peak in
E2 at the end of the second week, just prior to ovulation. In the
third week, formation of the corpus luteum after ovulation leads
to a two-week elevation of P4 and secondary elevation of E2. In
the final week, both E2 and P4 plateau and then fall precipitously
in the final few days prior to menses onset. In the paragraphs that
follow, we outline what is known about the pathophysiology of
PMS/PMDD. Since the pathophysiology of PME of depression
has been found to be unique from PMDD but has yet to be
clarified in its own right (i.e., PME of depression is resistant to
various effective treatments for PMDD; Bixo et al. (77), Freeman
et al. (78), Peters et al. (79)], we will focus our review below on
the role of reproductive steroid hormones in PMS/PMDD (i.e.,
those with luteal phase confinement of symptoms).
As yet, studies have failed to demonstrate consistent
abnormalities in E2, P4, or ALLO hormone levels among
womenwith PMS/PMDD. Instead, premenstrual mood disorders
are thought to be caused by an aberrant response to normal
fluctuations in reproductive steroid hormones. A series of
clinical trials demonstrate that GnRH agonists effectively treat
the symptoms of PMDD by creating a medical menopause
characterized by low, stable levels of reproductive steroid
hormones [reviewed inWyatt et al. (80)]. However, experimental
studies demonstrate that addback of luteal phase levels of E2,
P4, or their combination causes a resurgence of PMDD-like
symptoms not observed in controls and not precipitated by
placebo (18). Recently, Schmidt et al. (22) have also demonstrated
that this symptomatic response to addback of reproductive
steroid hormones is time-limited, remitting after 1 month of
stable addback. This series of experiments suggests that it is
the postovulatory changes in reproductive steroid hormones—
and not the elevated luteal hormone levels themselves—that
precipitate symptoms in PMS/PMDD.
Further, experimental work demonstrates that PMS/PMDD
are caused by an abnormal sensitivity to normal postovulatory
surges in reproductive steroid hormones rather than
perimenstrual reproductive steroid hormone withdrawal.
Schmidt et al. (81) tested the effects of reproductive steroid
hormone withdrawal on symptoms of PMDD in three groups
of women; one third received placebo in the midluteal phase,
and the other two thirds received mifepristone, a competitive
P4 receptor antagonist that causes menses (breakdown of
endometrium) and luteolysis (involution of the corpus
luteum and associated E2 and P4 withdrawal). Of those
receiving mifepristone, half also received human chorionic
gonadotropin (HcG), which rescued the corpus luteum,
preventing reproductive steroid hormone withdrawal (while
still allowing mifepristone-induced menses for blinding
purposes); the other half of those on mifepristone received a
placebo, which resulted in both mifepristone-induced menses
and mifepristone-induced luteolysis with attendant early
reproductive steroid hormone withdrawal. The authors reported
no significant mood differences between the three groups
(midluteal induction of early menses and hormone withdrawal
with mifepristone + placebo injection, midluteal induction
of early menses but normal midluteal hormone levels with
mifepristone + HcG injection, and a natural midluteal phase
without menses or hormone withdrawal on dual placebos).
This indicates that neither initiation of menses nor induction
of hormone (and attendant ALLO) withdrawal alone underlie
symptoms of PMDD. In combination with the results of studies
described above, we conclude that an abnormal post-ovulatory
sensitivity to surges in reproductive steroid hormones (and not
a perimenstrual sensitivity to reproductive steroid hormone
withdrawal) likely precipitates the symptoms of PMS/PMDD.
Sensitivity to Changes in ALLO and the
HPA Axis in PMS/PMDD
Although general psychiatric populations have been found to
show reduced biosynthesis of ALLO (46), a recent experimental
metabolomics study demonstrated normal P4 metabolism to
GABAergic neurosteroids (e.g., ALLO) in PMS/PMDD relative
to controls (82). Instead of being caused by a general reduction
in ALLO levels (e.g., similar to that observed in depression or
PTSD), evidence is accumulating to support the notion that
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PMS/PMDD are caused by an abnormal neural sensitivity to
normal ALLO changes. A recent randomized controlled trial
demonstrated preliminary evidence for efficacy of dutasteride in
PMDD, a 5α-reductase inhibitor that prevents the metabolism
of P4 to its GABAergic neurosteroid metabolites such as ALLO
(83). This indicates that it is an altered sensitivity to postovulatory
ALLO surges, and not solely E2 or P4 surges, that triggers
symptoms of PMS/PMDD.
This altered response to ALLO surges in PMS/PMDD might
be caused by abnormal or insufficient plasticity of the GABARAR
receptor in response to the postovulatory rise in ALLO [e.g.,
an upregulation of the α4βδ GABARAR receptor; Shen et al.
(84)]. This argument is supported by preliminary evidence
for the efficacy of UC1010 (Sepranolone), which acts as an
antagonist at the neurosteroid binding site of the GABARAR
receptor at which ALLO is active, thereby preventing the adverse
effects of ALLO surges in PMDD (77). Notably, these combined
results would appear to rule out insufficient ALLO biosynthesis
(either peripherally or in the CNS) as the cause of PMS/PMDD,
since blockade of the neurosteroid binding site is therapeutic
rather than further triggering PMS/PMDD symptoms. In sum,
it appears that symptoms of PMS/PMDD are probably related to
an abnormal regulation of the GABARAR receptor in response to
postovulatory surges in ALLO.
Perimenstrual studies demonstrate that GnRH-agonist
suppression of reproductive steroid hormones blunts the
normative HPA axis response to stress in healthy women, and
that addback administration of luteal levels of P4—and not
E2—recapitulate the luteal phase potentiation of the HPA axis
response to stress (85, 86). Since ALLO is known to limit the
extent and duration of the HPA axis response to stress, it is likely
that luteal phase increases in P4 potentiate the HPA axis response
through other (e.g., genomic) mechanisms (87).
While the HPA axis and related cortisol output has been
extensively studied in observational studies of PMS/PMDD,
there is no consistent evidence for abnormal cortisol levels
or responses to stress in PMS/PMDD [reviewed in Kiesner
and Granger (88)]. Rigorous experimental studies (in
which women with and without PMDD are tested during
ovarian suppression with GnRH agonist, E2 addback, and
P4 addback) demonstrate no differences in reproductive
steroid hormone regulation of the HPA axis among women
with PMS/PMDD compared to controls, including normal
effects of administration of reproductive steroid hormones
on output of CRH by the hypothalamus, ACTH by the
pituitary, and glucocorticoids by the adrenals, as well as normal
effects of administration of reproductive steroid hormones
on glucocorticoid receptor feedback (85). Therefore, this may
be an area of pathophysiology in which PMS/PMDD differs
from other mood disorders such as unipolar depression and
may also differ from the pathophysiology of peripartum or
perimenopausal mood episodes (compare e.g., also sections
HPA Axis Dysregulation and the Neurosteroid Hypothesis
of Peripartum Depression and HPA Axis and GABA-ergic
Mechanisms in Perimenopausal Depression).
Despite normal regulation of the HPA axis by reproductive
steroid hormones (85), there is some evidence to indicate
that trauma and recent life stressors increase the severity of
hormone-related symptom expression in PMS/PMDD. Cross-
sectional studies have observed a correlation between traumatic
experiences and retrospectively-self-reported PMDD symptoms
[a method known to have a very high false positive rate; Pilver
et al. (89)]; however more rigorous studies in which PMDD
was prospectively-diagnosed did not find increased exposure to
trauma in individuals with PMS/PMDD (90). PMDD patients
with high ALLO levels have been found to show blunted
nocturnal cortisol levels in comparison to healthy controls who
had low ALLO serum concentrations. It also has been argued
that diurnal secretion of cortisol may be influenced by ALLO
levels during the luteal phase (91). However, these findings
do not replicate in another experimental study on PMDD,
where affected women did not show altered ALLO metabolism
following ovarian suppression and E2 or P4 addback (82).
Nonetheless, a longitudinal study of patients with prospectively-
diagnosed PMDD found that the strength of the daily link
between P4 levels and symptoms was stronger in patients with
histories of trauma, which may indicate that trauma increases the
severity (rather than the occurrence) of hormone sensitive mood
symptoms in PMS/PMDD (92). In addition to historical trauma
exposure, current life stressors may exacerbate or prolong the
mood effects of hormone sensitivity in women with PMS/PMDD.
In one observational study, cycles preceded by higher-than-
usual perceived stress showed greater premenstrual increases in
mood symptoms (93). Another prospective study of medical
students who were (or were not) beginning a stressful night
shift assignment found greater increases in premenstrual mood
changes among students starting the stressful rotation (94). Since
the HPA axis has been found to be normal in PMS/PMDD, more
work is needed to understand how internal and environmental
stressors may interact with hormone sensitivity to increase
cyclical mood symptoms.
Brain Imaging Findings on PMDD
Neuroimaging studies of PMDD remain rare and of mixed
quality [for a thorough review and critique of this literature,
see Comasco and Sundström-Poromaa (95)]. However, a
few patterns of interest have emerged and have begun to
shed light on some possible neurobiological underpinnings of
PMDD. A few studies comparing gray matter volumes between
women with PMDD and healthy controls have observed larger
posterior cerebellum and increased gray matter density in the
hippocampal cortex, as well as lower gray matter density in
the parahippocampal cortex (96, 97). Some studies have noted
differences in brain function between those with and without
PMDD regardless of cycle phase, including altered activation in
the dorsolateral prefrontal cortex (98) and increased amygdala
response to negative stimuli (99). Other studies show differences
in how the cycle impacts brain function in PMDD. In a proton
magnetic resonance spectroscopy study comparing PMDD and
controls, cortical GABA decreased from the follicular to the
luteal phases in controls, but increased from the follicular
to the luteal phase in PMDD (100). Amygdala function may
also respond abnormally to progesterone in PMDD; one study
found that GABAergic progesterone metabolites predicted lower
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amygdala reactivity to social negative pictures in healthy controls,
whereas the opposite relationship was found in those with PMDD
(99). Finally, one study found that, relative to healthy controls,
women with PMDD showed greater late luteal phase increases
in activation of the left insula during a cognitive processing task
(101). In sum, while there are some promising findings that
may point to the underlying neurobiology of hormone sensitivity
in PMDD, more systematic, and experimental imaging work is
required to move this area forward.
Interactions Between the Serotonergic and
the GABAergic system in PMDD
As discussed by Birzniece et al. (66) SSRIs may increase
inhibitory processes in the limbic structures of the brain
involved in the emotional as well as cognitive regulation by
hyperpolarization of neuronal membranes enhancing GABA-
stimulated Cl− uptake. Women diagnosed with PMDD have
been shown to have a decreased sensitivity toward GABAA
receptor active substances, especially during the luteal phase
(102), when altered serotonergic activity is also observed
[reviewed in Hantsoo and Epperson (103)]. Serotonin reuptake
inhibitors represent an effective treatment, especially by means
of intermittent administration in the luteal phase (104). One
possible mechanism is that the SSRI treatment increases
metabolism of progesterone to allopregnanolone and normalizes
the tolerance to neurosteroids observed during the luteal phase
in PMDD (105). However, there is also some evidence that the
benefit of SSRIs in PMDD is dependent on their serotonergic
mechanisms (106), since coadministration of the serotonin
receptor antagonist metergoline (vs. SSRI alone) is able to
undermine the benefit of SSRIs in PMDD. Therefore, more
work is needed to determine whether alterations of serotonin
and GABA systems represent additive or interactive risk factors
for PMDD.
Genetic Factors in PMS/PMDD
Although a few studies have identified single-nucleotide
polymorphisms (SNP) that differentiate PMS/PMDD cases
from controls (107, 108), caution should be exercised when
interpreting such studies (109). However, with a focus on
epigenetic alterations a recent study of lymphoblastoid cell
line cultures from women with PMS/PMDD and controls has
demonstrated notable abnormalities in the cellular epigenetic
processing of reproductive steroid hormones in PMDD,
including altered mRNA expression of several ESC/E(Z)
complex genes, both in control samples and in samples treated
with E2 and P4 (110). Epigenetic changes across the menstrual
cycle and in response to hormonal manipulations may represent
a critical area of research to move forward our understanding of
the pathophysiology of PMS/PMDD.
PERIPARTUM MOOD DISORDERS
Diagnostic codes for peripartum mood disorders in the ICD and
DSM diagnostic manuals differ and there is not a consistent
definition. The ICD-10 (111) restricts to either pregnancy
or postpartum onset, while in the DSM-5 (71), there is
a “peripartum onset” specifier that includes both pregnancy
and postpartum in the affective disorders section. ICD-11
distinguishes between mild, moderate, and severe episodes of
depression and also between single and recurrent episodes,
as well as with and without psychotic symptoms that are
supplemented with “current episode perinatal” in the codes ICD
11 6A70-6A71 (World Health Organization ICD-11 Browser,
Version 2019).
Up to 25% of women experience significant depressive
symptoms following pregnancy (7, 112), however, it is estimated
that about 80% of postpartum depression (PPD) cases are not
recognized and officially diagnosed, which means that only 20%
of affected women receive the treatment they need. Notably,
affective symptoms are often already present during pregnancy
and the presence of such symptoms in pregnancy has been shown
to be among the strongest predictors of PPD (113).
Reproductive Hormonal Changes During
the Peripartum Period
For a comprehensive overview concerning normal reproductive
steroid hormone fluctuations see Schock et al. (114). It
has long been hypothesized that withdrawal of reproductive
steroid hormones occurring in the postpartum period plays
an important role in the etiology of PPD. One of the first
studies providing strong evidence of this used a hormone
manipulation paradigm simulating the reproductive steroid
hormone withdrawal after parturition among women with a
history of PPD and among women without. It was shown that the
same hormone manipulation procedure produced a significant
increase in depressive symptoms among the women with a
history of PPD but not among women without. This suggests that
PPD may result from an increased sensitivity to the changes in
reproductive steroid hormones that characterize the postpartum
period (19). Also, there are several small RCTs finding hormone
therapy to be an effective treatment for postpartum depressive
symptoms which also supports the role of hormonal withdrawal
in the etiology of PPD (115).
While the mechanisms by which withdrawal from E2 and
P4 triggers depressive mood in a subset of postpartum women
are not fully understood, there is a growing body of research
suggesting that increased sensitivity to psychosocial stress may
play a role. For example, a history of stressful life events is a
strong predictor of the development of PPD (116). Furthermore,
psychological (e.g., adjustment to the role as a mother) and
physiological stressors (e.g., sleep deprivation) markedly affect
subjective well-being, affective symptoms, and physiological
stress responses after birth (117). In addition, standard laboratory
experiments have shown that stress-susceptibility prior to birth
can predict postpartum mood symptoms (118).
HPA Axis Dysregulation and the
Neurosteroid Hypothesis of Peripartum
Depression
Stress increasing factors for depression and anxiety for instance
during pregnancy have been reviewed as risk factors for these
disorders, e.g., lack of partner or of social support, a history of
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abuse or of domestic violence; personal history of mental illness;
unplanned or unwanted pregnancy; adverse events in life and
high perceived stress; present and past pregnancy complications
and pregnancy loss (119). In light of the important role that
psychosocial stressors and increased sensitivity to such stressors
likely play in the development of peripartum depression, it is
not surprising that there is more and more evidence implicating
alterations in HPA axis functioning in the etiology of peripartum
depression (119). The cortisol response of pregnant women (and
new mothers, respectively), with a vulnerability for depression
during reproductive transitions may vary as a function of the
social support they receive, as well as other stress reducing
interventions they may have access to (120). Pregnant women
suffering from depression show a significantly higher cortisol
response to stressors compared to their controls (118). Pregnant
women with prepartum depression and/or anxiety disorder
measured in the third trimester have also been found to show
a higher cortisol response to stress, but only in the case of
comorbidity with e.g., anxiety disorders (121). Also, higher mid-
term CRH levels were associated with PPD (122). Further, a
significant correlation between the cortisol awakening response
and major depression was found in pregnant women (123).
Setting pre-partum and postpartummood problems into context
in peripartum research can contribute to our understanding of
RMDs, as we see a continued rise in E2 in the third trimester
accompanied by an increase in mood symptoms and ultimately
also the peak in depressive symptoms in the second and third
postpartum week where accumulated pre-partum psychiatric
burden adds up with postpartum hormone withdrawal (124).
In recent years, research on peripartum depression has
evolved toward examining the role of neurosteroids (e.g.,
ALLO and DHEA) in the genesis of the disorder and a
“hormone-sensitive” phenotype of postpartum depression has
been proposed [e.g., (125)]. Dehydroepiandrosterone (DHEA)
plays a particular role in affective dysregulation and abnormal
DHEA secretion has been found inmajor depression [e.g., (126)].
Also, DHEA has been found to have anti-depressive effects
on both, men and women (127). However, the neurosteroid
ALLO has increasingly moved into the center of attention.
Regardless of PPD or a healthy state, postpartum women show
reduced cortical GABA and ALLO, comparable to healthy
women in their follicular phase (128), which also suggests
that normal absolute hormone levels are not the underlying
cause, but the fluctuation of hormones. There appears to be
a vulnerability or sensitivity in a subpopulation of women
to the development of peripartum depression (125). It has
been shown that the increasing levels of neuroactive steroids
(NAS) during pregnancy are crucially related to modifications
in the expression of specific GABARA Rreceptor subunits (129).
During pregnancy and after parturition, due to major changes
in reproductive hormones, the expression of the GABARAR
receptor δ subunit is altered (52, 130, 131). ALLO levels increase
during pregnancy and the GABARA Rreceptor δ subunit is
downregulated. After parturition ALLO levels decrease rapidly,
the GABARA R receptor δ subunit is recovered. Based on research
with rodents it has been hypothesized that i0n women at risk
for PPD, this regulatory mechanism seems to be compromised.
For a comprehensive review on these mechanisms, also with
respect to the stress axis we recommend the most recent
work by Walton and Maguire (132). Altered NAS and GABA
profiles have been found in women at risk for peripartum
depression. Peripartum GABA levels in women at risk for PPD
manifested at a significantly lower level compared to healthy
controls (133). In pregnant women whose stress regulatory
mechanisms are compromised with respect to this GABARAR
receptor complex (for genetic or epigenetic reasons), there can be
extremely high stress levels. So, the vulnerability to stress-related
psychological disorders like anxiety and depression increases
significantly, depending also on the potency of exogenous
stressors such as social stressors (119). Neurosteroids play
a key role in endogenous stress modulation (134). In sum,
as it is hypothesized that a flexible plasticity of GABARAR
receptor subunits is compromised in PPD women, suggesting
a dysfunction in adapting to peripartal hormonal changes. This
would also correspond with the key notion proposed by Rubinow
and Schmidt (23) that RMDs represent a problem of switching
between affective states.
Brain Imaging Findings on Peripartum
Depression
Women with PPD have been found to show altered functional
connectivity and activity in brain areas key for executive
functions as well as emotion and reward processing. For a
comprehensive review of structural and functional connectivity
and molecular imaging research please see Duan et al. (135).
Neuroimaging findings on PPD center around a decreased
resting state functional connectivity between the anterior
cingulate cortex, amygdala, hippocampus, and the dorsolateral
prefrontal cortex against the background of falling progesterone
and ALLO levels after giving birth (136). First fMRI and
spectroscopy studies have started to bring GABA and ALLO
mechanisms on screen in peripartum depressed women (137).
GABA levels were found to be correlated with marked differences
in the connectivity of the dorsomedial prefrontal cortex within
the default mode network, which also correlated with depression
cores in PPD women (137). Also, compromised connectivity has
been reported between the amygdala and prefrontal cortex, which
implies dysfunctions in emotion processing (138). Concerning
an overlap between MDD and PPD functional abnormalities,
findings are conflicting. While some authors argue that the
network dysfunctions are identical between the disorders (138,
139), others argue that only perimenarchal depressive disorders
share the same neuroimaging findings with MDD as mentioned
earlier (62). Here, it has to be considered that the majority of
neuroimaging studies had included cases suffering from PPD
and MDD as well. Future research will have to make clear
distinctions in this respect. In particular the hypothalamus,
the amygdala, the anterior cingulate, the orbitofrontal and
dorsolateral prefrontal cortices, the insula and the striatum seem
to be key areas of interest to the etiology of PPD (140). In
sum, fMRI studies demonstrate hypoactivation of brain regions
studied in women with postpartum depression compared to
those without PPD (62).
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Interactions Between the Serotonergic and
the GABAergic system in Peripartum
Depression
The link between the serotonergic system and the GABAergic
system in the peripartum period is a research area of increasing
interest. Antidepressant treatment with SSRI’s has been shown
to restore plasma and CSF ALLO levels in association with
improvements in depressive symptoms (141, 142). Therefore,
increasing levels of ALLO may play an important role in the
antidepressant and anti-anxiety pharmacological effects of SSRIs
(46). In addition, the recent FDA approval of brexanolone
(Zulresso) for the treatment of postpartum depression provides
further evidence that a positive allosteric modulator of GABA-
A improves depression in the postpartum period (143, 144).
However, the relation between brexanolone treatment in
women with PPD and associated serotonin levels has not yet
been shown.
Genetic Factors in Peripartum Depression
There is a growing interest in understanding the genetic signature
of peripartum depression. The literature consists largely of
smaller genetic epidemiological and linkage studies (145–149).
More recently, a study of the heritability of PPD using the
Swedish national twin register estimated the heritability of PPD
to be 54 and 44% using twin and sibling designs, respectively.
In this same population, the heritability of depression occurring
outside of the peripartum period was estimated to be 32%
(150). These findings suggest that one-third of the genetic
contribution to peripartum depression was unique and did not
overlap with the genetic component of depression outside of the
peripartum period. Therefore, the increased heritability, as well
as increased genetic overlap with other mood disorders, makes
peripartum depression an interesting candidate for future genetic
investigations. Genetic aspects represent an important person-
level variable in a potential etiological model of reproductive
disorders, as will be shown in the graphical abstract introduced
below as a precursor to such an etiological model (section
Discussion: From “Reproductive Steroid Hormone Sensitivity” to
“Steroid Hormone Sensitivity”).
Underlying pathophysiology can be used to probe the
heterogeneity of peripartum depression. We hypothesize
there may be different phenotypes of peripartum depression.
Evidence from the international PACT Consortium (Postpartum
Depression: Action Toward Causes and Treatment), has worked
to help define the heterogeneity of peripartum depression
and has described different phenotypes based on severity
of symptoms, timing of onset of depressive symptoms, and
presence of suicidal thoughts, race, and ethnicity among
others (151–153). The PACT Consortium is also interested
in the underlying genetic signature of PPD and is currently
working on a large-scale Genome-wide association study of
PPD (154). These approaches will increase our understanding
of phenotypic differences but there remains an important gap
between defining phenotypes and understanding the underlying
mechanistic differences.
Consequently, the next step is to investigate the underlying
pathophysiology that may be unique to the observed
heterogeneity in PPD. For example, it could also be hypothesized
that women with a susceptibility to fluctuations in reproductive
steroid hormones who already show signs of depression during
pregnancy may not develop a natural tolerance toward ALLO
changes during pregnancy and postpartum, which could imply
that they show an increased sensitivity in their key receptors for
ALLO. The recent approval of brexanolone, a formulation of
ALLO, in the US for PPD is highly relevant to this hypothesis.
The women studied in the clinical trials had severe PPD with
onset of symptoms in the third trimester or within the first
month postpartum (143, 144).
PERIMENOPAUSAL MOOD DISORDERS
The menopausal transition describes the reproductive phase
transitioning from regular menstrual cycles to the complete
cessation of menses, which marks the onset of menopause.
Between ages 42 and 55, nearly all women experience the
menopause transition, which, on average, extends 5–6 years
leading up to the last menstrual period [e.g., Avis and McKinlay
(155), Oldenhave et al. (156), Treloar (157)]. A recent review
article identified 12 cross-sectional studies comparing rates of
elevated depressive symptoms in pre- and peri-menopausal
women and concluded that 45–68% of perimenopausal women,
vs. only 28–31% of premenopausal women, report clinically
significant elevations in depressive symptoms (8). Currently,
perimenopausal depression does not have a diagnostic code that
is distinct from major depression in either the ICD-10 (111) or
the DSM-5 (71). ICD-11 still does not code for perimenopausal
depression- this RMDwould have to be coded by “Other specified
menopausal and perimenopausal disorders, GA20Y” (World
Health Organization, ICD-11 Browser, Version 2019).While the
Center for Epidemiologic Studies Depression Scale (CES-D)
is the questionnaire that is most commonly used to assess
depressive symptoms in the menopause transition, there has
been a call for a menopause-specific scale that would better
take both physical and affective symptoms into consideration
(158). In this review, we focus on reproductive hormonal
fluctuations as a critical factor in perimenopausal problems.
However, for the sake of completion- and as will also be referred
to in the concluding research outlook- other stress responsive
systems also need to be taken into consideration. For instance,
the immune system, as well as the thyroid hormonal system
can be at the root of climacteric symptoms (159). So it is
of utmost importance to rule out other causes like thyroid
disorder or autoimmune disorder (160) in women presenting
with perimenopausal depression. Also, the links between the
reproductive hormonal and the immune system have to be kept
in mind, in particular in the context of Hormone Therapy in the
Perimenopausal Transition (161). Fluctuations in Progesterone
levels have also been shown to alter immune responses and
susceptibility to infections at diverse mucosal sites including
the genital, gastrointestinal, and respiratory tracts. So the
immunomodulatory effects of Progesterone-based compounds
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need to be given thorough consideration in the treatment
of perimenopausal symptoms (162). Reproductive hormonal
changes seem to be at the core of those interactions with
other hormonal system disorders as well as immunological
disturbances, so for this review, we focus on fluctuations in
reproductive hormones.
Reproductive Steroid Hormone Changes of
the Menopause Transition
The menopausal transition is characterized by several hormonal
changes, triggered by a diminishing number of ovarian follicles
and fluctuating levels of FSH (163). Beginning in the early
menopause transition and continuing into the late transition,
is the appearance of menstrual cycles that are characterized
by elevated luteal phase E2 levels, which can reach levels that
are as high as double those generally seen in the late follicular
phase (164, 165). E2 levels in the early follicular phase, on
the other hand, have been shown, at times, to reach lower
levels than typically observed in reproductive-aged women (166).
Furthermore, the low-E2 early follicular phase lengthens due to a
delayed ovarian response to FSH, resulting in a longer cycle (167).
While P4 levels remain intact throughout the early menopause
transition, luteal P4 is lower, on average, throughout the late
menopause transition (168). Anovulatory cycles, characterized
by low P4 but variable E2 levels, also become increasingly
common, with 60–70% of cycles being anovulatory in the late
transition (169).
Evidence that an Abnormal Sensitivity to
Normal Perimenopausal Reproductive
Hormonal Changes Contributes to
Perimenopausal Depression
Several studies implicate extreme fluctuation in E2 in the
development of perimenopausal depression. Perhaps the
strongest evidence comes from a placebo-controlled study by
Schmidt et al. (20), which experimentally induced E2 withdrawal
using an E2 patch and observed a marked increase in depressive
symptoms in the following weeks among women with a history
of perimenopausal depression that had been responsive to
E2, but not among those without. These findings are in line
with three studies observing a relationship between greater E2
fluctuation and elevated risk for depressive symptoms (170–
172), as well as a recent placebo-controlled RCT examining
the efficacy of transdermal E2 in the prevention of depressive
symptoms among perimenopausal and early postmenopausal
women (173). In this 12-month study, the rate of clinically
significant depressive symptoms was found to be lower among
women assigned to transdermal E2 (100 ug/day) vs. placebo
(17 vs. 32%). Interestingly, women in the early menopause
transition were found to experience the greatest mood benefit,
perhaps suggesting that its effects were due to its ability to
stabilize the hormonal environment rather than increase low
E2 levels.
HPA Axis and GABA-ergic Mechanisms in
Perimenopausal Depression
In light of the importance of both hormonal and psychosocial
contributions to the development of perimenopausal depression,
it has been hypothesized that the hormonal environment of the
menopause transition, particularly increased E2 fluctuation, may
interact with the stress axis to confer an increased sensitivity
to psychosocial stress and increased vulnerability to mood
disturbance (163). However, when compared to PMDD and
peripartum depression, research directly examining this potential
interaction is greatly lacking. In one study cited above (163), a
significant interaction was found between E2 fluctuation and the
presence of major stressful life events such that E2 fluctuation
was predictive of depressive mood among women experiencing
one or more events but not among those without baseline stress.
Furthermore, the 12-month RCT of transdermal E2 cited above
found that the mood benefits of E2 were enhanced among
women with greater baseline stressful life events (173). While
two studies to date suggest that basal cortisol levels are unrelated
to depressive mood in the menopause transition (126, 174),
there is some evidence that altered diurnal cortisol patterns may
be associated with perimenopausal depressive symptoms. For
example, an ancillary of the Study of Women Across the Nation
(SWAN) including 408 midlife women, found that depressive
symptom score was associated with a flatter diurnal cortisol slope
(175). A second study has also observed a relationship between
greater weekly changes in E2 and elevated morning cortisol
among women with current perimenopausal depression but not
among euthymic controls (171, 172). This latter finding would
be consistent with the notion that increased HPA axis activation
following E2 (and, in turn, ALLO) fluctuations may play a role in
perimenopausal depression.
The potential involvement of the GABAergic system and
GABAergic neurosteroids, such as ALLO, in the etiology of
perimenopausal depression remains largely theoretical as little
clinical research directly testing its contribution has been
conducted. In a rat model, ovariectomy has been shown to greatly
reduce brain ALLO concentrations while administration of 17β
estradiol (0.1 or 1 ug per day for 14 days) has been shown to
restore ALLO to pre-ovariectomy levels in the hippocampus and
hypothalamus (176), an effect that is likely explained by E2’s
modulation of the enzymes involved in the conversion of P4
to ALLO, 5α-reductase, and 3α-hydroxysteroid dehydrogenase
(177). It is therefore possible that the shift between the more
extreme E2 levels that characterize the menopause transition,
either alone or in conjunction with P4, may result in a more
dramatic change in ALLO concentrations than would be seen
in a typical menstrual cycle, thus triggering depressive mood
in a subset of women for whom the GABARAR receptor fails
to adjust to the rapid change in neurosteroid levels. These
women may also be more prone to depressive mood when first
experiencing a hypogonadal state in the late perimenopausal and
early postmenopausal phases: in line with this possibility, a recent
study examined the correlation between serum ALLO levels and
mood in 140 late perimenopausal and early postmenopausal
women and found that ALLO was negatively correlated with
feelings of guilt among the early postmenopausal women (29).
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Brain Imaging Studies in Perimenopausal
Depression
To date, there has been little research examining the neural
correlates of perimenopausal depression. One study by Berent-
Spillson et al. (178) compared brain activation patterns in
euthymic pre-, peri-, and postmenopausal women in response
to an emotion identification task. Perimenopausal women were
found to have a negative bias in identifying the emotions
exhibited by the neutral faces; furthermore, both peri- and
postmenopausal women exhibited less limbic activation and
greater activation of the tempo-parietal-occipital junction (178),
a pattern considered to indicate a more cognitively-mediated
decision-making process than an emotionally-mediated one. The
cognitively-mediated decision-making process was associated
with greater depressive symptoms across all three groups.
Laboratory sessions occurred in the early follicular (low E2) phase
among cycling women, though E2 levels did not correlate with
any of the outcomes assessed, suggesting that these differences
are not related to differences in hormone levels, but that perhaps
greater hormonal instability and/ or hormonal withdrawal
is the hormonal driver behind these observed differences.
Other imaging studies, while not conducted in perimenopausal
women per se, have used experimental hormonal manipulations
in other populations to inform our understanding of the
menopause transition. These studies have primarily focused on
the involvement of the serotonergic system and are therefore
described in the next section.
Interactions Between the Serotonergic and
the GABAergic system in Perimenopausal
Depression
As with PMDD and PPD, the potential involvement of
other neurotransmitter systems apart from GABA have been
investigated in perimenopausal depression, with the serotonergic
system receiving the most attention. Neocortical serotonin
transporter binding (resulting in greater serotonin reuptake
and therefore lower serotoninergic tone in this region) has
been found to increase in response to an experimentally
induced hypogonadal state mimicking that observed in
the late menopause transition (49). Furthermore, cortical
serotonin transporter binding has been found to decrease
(179) while 5-HTR2AR receptor binding has been found
to increase (180) following the administration of estrogen
therapy in postmenopausal women. One final study examining
serotoninergic influences in perimenopausal depression
examined the interaction between tryptophan depletion and
estradiol treatment on brain activation during an emotion
identification task among early postmenopausal women (181).
Specifically, it was found that tryptophan depletion reduced
activation of the dorsolateral prefrontal cortex and medial
frontal/cingulate gyrus compared to sham depletion but that
this effect was eliminated with the administration of estradiol.
Also relevant to the potential involvement of the serotonergic
system in perimenopausal depression is one study comparing
the volume of monoamine oxidase A, an enzyme involved in
the degradation of serotonin, in the prefrontal cortex of pre-,
peri-, and postmenopausal women (182). This study found that
on average, women in the perimenopausal age range (41–51
years) had 34% greater monoamine oxidase A volume compared
to young reproductive-aged women and 16% greater than
older women.
The above studies implicating the serotonergic system in
the etiology of perimenopausal depression are consistent with
research finding that selective serotonin reuptake inhibitors
(SSRIs) are an effective treatment for perimenopausal depression
[see Maki et al. (183) for review]. Taken together, these research
findings suggest that the serotonergic system has a role to play
in the etiology of perimenopausal depression; however, in light
of the complex interactions that are well-documented between
the GABAergic and serotonergic system, this certainly does
not preclude the simultaneous involvement of the GABAergic
system as more thoroughly provided above. Interactions between
the two systems remain to be explored in depth in the
perimenopausal context.
Genetic Factors in Perimenopausal
Depression
Current research examining potential genetic contributions to
the development of perimenopausal depression is limited. The
largest study to date involved 1,538 pre- and perimenopausal
women ages 42–55 participating in the Study of Women’s
Health Across the Nation (SWAN). In this study, specific
polymorphisms of three genes involved in the metabolism of
E2 and estrone (E1)–the CYP1A1 gene among Caucasian and
African American women, the 17HSD gene among Chinese
women, and the CYP 19 gene among Japanese women –
were found to be associated with an increased risk of elevated
depressive symptoms (184). However, neither the ESR1 nor the
ESR2 gene, respectively, encoding estrogen receptors α and β,
were found to be relevant for risk of depressive symptoms.
A second study including 488 women ages 42–68, of which
156 were perimenopausal (54 depressed and 102 controls),
observed depression-related differences in the frequency of
polymorphisms for the MAO-A and MTHFR genes, which are
relevant for monoamine oxidation and methylation, respectively.
However, several other genes, including the ESR1 gene, several
genes involved in serotonergic transmission (5HTR2A, 5HTR1B,
and 5HTR2C), and the GABRB1 gene, which codes for a
subunit of the GABARAR receptor, were not found to be
relevant for depression in the perimenopausal subgroup (185).
However, statistical power to detect such effects may have
been limited. A third study including 391 Chinese women
(191 with major depressive disorder, 200 controls) found that,
among women ages 40–60, a gene-by-environment interaction
between negative life events and allelic variations of the ESR2
gene could be seen in relation to major depressive disorder.
However, no such interaction was observed among younger
women, raising the possibility that the hormonal environment
of the menopause transition, when combined with negative life
events, may trigger depressive mood in women with a genetic
predisposition involving the ESR2 gene. However, there is clearly
much work to be done in clarifying the role that genetics
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play in the etiology of perimenopausal depression. Future
research that more carefully defines the menopause transition
via menstrual bleeding patterns using the Stages of Reproductive
Aging Workshop +10 (STRAW+10) criteria (186), excluding
postmenopausal women, is needed. The STRAW+10 guidelines
define the early menopause transition based on the appearance
of a menstrual cycle length 7+ days shorter or longer than usual
and the late menopause transition based on the occurrence of two
skipped cycles, but <1 year since the last menstrual period.
DISCUSSION: FROM “REPRODUCTIVE
STEROID HORMONE SENSITIVITY” TO
“STEROID HORMONE SENSITIVITY”
Based on the research findings presented in this review, the
following conclusions can be made with a fair degree of
confidence. First, rigorous hormonal manipulation studies have
demonstrated strong evidence that increased mood sensitivity
to changes in reproductive steroid hormones plays a key role
in the etiology of all three RMDs discussed—PMS/PMDD (18),
PPD (19), and PMD (20). The evidence that increased sensitivity
to ALLO fluctuation mediates the link between reproductive
steroid hormone changes and mood disturbance is quite strong
in the context of PMDD (83) and PPD (143). However, further
work is needed to examine the role that sensitivity to ALLO
fluctuation triggered by E2 or P4 fluctuation may play in the
development of perimenopausal depression. Although it seems
likely that genetic and epigenetic contributions play an important
role in conferring an increased sensitivity to ALLO fluctuation,
we are far from having a clear and consistent picture about the
specific genes involved.
A second assertion that can be made at this stage
of research on RMDs is that proximal psychosocial stress
increases susceptibility for mood disturbance in the context of
reproductive transitions. In the case of PPD and perimenopausal
depression, there is some evidence that HPA axis dysregulation
may either be a correlate of depressive symptoms or may play a
partial role in the development of mood disturbance. However,
the evidence for its role as a primary mechanism underlying the
etiology of these RMDs is relatively weak. More work is needed,
in particular also on PMDD, to identify the mechanisms by
which psychosocial stress may increase risk for and/or exacerbate
RMDs. Overall, the GABARAR receptor in specific subunit
combinations has been found to be a clear center piece in
these mechanisms between the stress hormonal axis and the
reproductive hormonal axis (37).
Third, the serotonergic system has also been implicated in
all three RMDs. However, we do not consider this body of
research as being contradictory to the simultaneous involvement
of GABAergic neurosteroids. Indeed, there is considerable
evidence suggesting that the serotonergic system is directly
modulated by these neurosteroids, including ALLO (46, 66). In
sum, clear linkages between the GABAergic and the serotonergic
systems have been found in the hippocampus, where serotonin
neurons frequently end at inhibitory GABAergic interneurons
(67). Also in vivo administration of low doses of a 5HT1A
receptor agonist that comes with anxiolytic effects enhances
GABA stimulated ClP− Puptake in cortico-hippocampal
synaptoneurosomes (68).
Recent literature presented earlier in this manuscript and also
in the following closes the circle to chronic stress or trauma in
childhood and youth, that has been established as a clear risk
factor for RMDs. Life stress that causes developmental insults
alters exactly those GABA-stimulated chloride mechanisms in
CRH neurons that constitute a key mechanism in the GABAergic
control of the HPA axis. These insights link to and build forth
on another research tradition that might benefit research on
RMDs: research on the psychobiology and molecular genetics
of resilience (187). The stress resilience of women with RMDs
seems to be severely compromised, which relates to the very
few existent studies on chronic stress and early life stress
reported earlier in this article in this context. In a recent and
comprehensive review on this topic, Hodes and Epperson (188)
elaborate on the existing findings concerning the difference
betweenmen andwomen in response to significant life stress. The
findings presented in this review confirm that life stress leading
to developmental insults, in particular during childhood and
puberty, is unmasked in women during hormonal fluctuations in
reproductive transitions. In women, this then manifests in stress-
related disorders such as depression, anxiety and posttraumatic
stress disorder. In contrast, prenatal and early postnatal stress
in men tends to manifest in other symptoms, such as those
pertaining to the autism spectrum disorders as well-attention-
deficit/ hyperactivity disorder. Further research in this particular
context of reproductive transitions and life stress in women could
hold valuable keys for improving the mental health of women
affected by RMDs.
Also, the brain imaging evidence presented in this article
shows that there is far more research needed to get a clear
picture of shared activation patterns in RMDs, as the studies
for each RMD are to heterogenous. In sum, a couple of aspects
have to be kept in mind when drafting a common etiological
model for RMDs: a clear difference in brain activation patterns
has been found between adult RMDs and premenarchal mood
problems, in that the latter was more akin to MDD. So it seems
sensible to draft a common etiological model for adult RMDs
only. In brain imaging studies GABA also played a central role,
in that GABAergic fluctuations were clearly tied to fluctuations
in the reproductive hormonal system. Also, decreasing ALLO
levels were found to be linked to changes in brain activation
pattern. So, brain imaging research also warrants the inclusion
of the GABAergic system and its activating neurosteroids into an
etiological model of RMDs. Not only the GABAergic mechanism
at the level of the PVN, activation patterns in the hippocampus,
but also compromised connectivity between the amygdala and
the prefrontal cortex played a major role in RMDs. Some
researchers found an identical network dysfunction and blunted
brain activation patterns for all RMDs. Concerning serotonergic
functioning hypogonadal states were found to come with greater
serotonergic uptake and decreased serotonin transporter binding
blunting serotonergic functioning in brain imaging studies. Both,
the serotonergic as well as the GABAergic system need to find a
place in a joint etiological model.
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In light of the above, in Figure 1 we present a graphical
abstract that could serve as a stepping stone for etiological
models for RMDs. In this graphic we integrate the supposed
shared mediators and moderators of RMDs. The model expands
on reproductive steroid hormone sensitivity as a concept
suggesting that rather than absolute steroid hormone levels,
it is the sensitivity toward relative changes in reproductive
steroid hormones (indicated by plus and minus symbols) which
drives affective, cognitive, and physiological outcomes (11).
These outcomes can also be expected to be closely related
and depend on situation-level variables of women such as
psychosocial stressors, as well as person-level variables suches
the genetic predisposition and epigenetic modifications of the
systems introduced and labeled in the following.
Therefore, we wish to add a focus on a sensitivity to stress
via altered GABARA Rreceptor and ALLO functioning on a
central nervous system level. Thus, we find it helpful to propose
to expand on the concept of reproductive steroid hormone
sensitivity toward introducing a more integrative concept of
“steroid hormone sensitivity”: We include both, a sensitivity in
the reproductive steroid system (RSS) as well as what we label
“the stress steroid system” (SSS). The dynamics between those
two steroid systems needs in-depth investigation. There are to
date no integrative data on these neuroendocrine dynamics and
their influence on women’s everyday life. Shared sensitivity to
normal reproductive steroid and neurosteroid concentrations
seems the focal point in the Stress steroid system for all
RMDs. Therefore, we position GABARA Rreceptor composition
as the central switch between the RSS and the SSS in our
graphical abstract, as this receptor regulates both systems as
reviewed earlier in this manuscript. The composition and
plasticity of this receptor seems key in whether the cross-talk
between the two steroid systems is flexible and adaptable during
hormonal fluctuations. Whether a woman with a vulnerable
genetic or epigenetic set-up including compromised GABAergic
modulation develops RMDs then depends on the social context,
including its stressors and supportive factors.
CONCLUSION
For all three RMDs manifesting in adult women’s life—PMDD,
PPD and perimenopausal depression—there is strong evidence
that biological factors (e.g., hormonal, genetic) and psychosocial
factors (e.g., daily-life burden/stressors) interact to predict
depressive symptoms. However, so far, much of the research has
tended to examine these mood disorders from one perspective
or the other, failing to consider how an individual’s biological
vulnerability may interact with her social environment to predict
the risk for depression. As a result, clinicians frequently have a
limited view of RMDs: obstetricians/gynecologists may tend to
view these disorders as being purely hormonal, responsive only
to pharmacological intervention, while counselors and social
workers may fail to appreciate the degree to which biological
influences play a role.
Furthermore, despite increasing evidence that the RMDs may
have much in common, they are still being investigated in
isolation, with research teams specializing in one disorder or the
other. This is also reflected in the diagnostic manuals ICD [e.g.,
(111)] and DSM-5 (71), where these disorders are spread across
different diagnostic categories of codes. RMDs still have to find
their adequate place in diagnostic manuals and it is continued
research on RMDs that is paving the way for this.
Expanding our perspective toward the more comprehensive
concept of “Steroid Hormone Sensitivity” that integrates
interactions between both, the reproductive steroid system
(RSS) and the stress steroid system (SSS) might serve as
a neuroendocrine basis for a better understanding of the
underlying differential stress sensitivity experienced by affected
women in daily life. Psychosocial stress effects manifesting
in affective as well as cognitive symptoms may be of
particular importance in these mechanisms. Compromised in
their cognitive functioning and in turn stressed by these
disabling symptoms, these women may spiral down in a
vicious circle between affective, physiological and cognitive
symptoms ultimately resulting in what we diagnose as RMDs.
Researchers in both research traditions on depresssion- those
on reproductive steroids as well as those on stress steroids-
seem to be more and more turning toward abnormalities in
receptor plasticity. The GABARA RReceptor could be the key
switch between the reproductive and the stress steroid system
with mounting evidence at a subunit level within this receptor
complex: a compromised plasticity required during hormonal
fluctuations. Concluding from our review, the role of the δ
subunit within the αR4Rβδ GABA Receptor seems to be key in
a successful endocrine modulation of reproductive transitions in
an environment marked by social stressors.
Working with a common etiological model may not only
help us all to proceed in our joint understanding of RMDs,
but it may also facilitate the development of new therapeutic
approaches combining psychosocial and neuroendocrine aspects.
Detecting psychosocial stressors such as the lack of support
and finding solutions for them is one of those aspects. From
a neuroendocrine point of view, elevating ALLO levels has
been discussed as a therapeutic approach to stress-related
disorders (46). The FDA approval of a formulation of ALLO
(Brexanolone) in the treatment of postpartum depression has,
therefore, broad implications for our field. Others have also
focused on the translocator protein (18kDa) (TSPO) which
is key for neurosteroidogenesis (189) or a novel, synthetic,
neuroactive steroid SGE-516 to improve postpartal depression-
like symptoms in mice (190). Overall, the role of GABARA
RReceptor composition for the activation of the receptor by
neurosteroids (37, 46) should be at the center of pharmacological
endeavors. In this context there is still far more in-depth evidence
needed for the epigenetic regulation of GABAergic transmission.
In depression research addressing GABAergic deficits means
moving from the mere treatment of the symptoms of depression
toward correcting causal neurochemical imbalances.
From a methodological point of view, we encourage the
use of parallel methodologies across the three RMDs and
suggest testing for common neuroendocrinological, genetic
and psychosocial contributors to these disorders. Several
methodological challenges will have to be carefully taken into
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account: the adequate measurement points in all disorders;
interaction effects between reproductive steroid hormones and
sex hormone binding globulin (SHBG), dehydroepiandrosterone
DHEA and androgen measurement; inflammation markers;
the choice of biomarkers for genetic phenotyping (such as
serotonin, genotyping receptors, but also transporters); other
neurotransmitters, targeting GABA receptors and ALLO in
humans. With respect to psychosocial factors, confounding
factors such as aging and self-image in the case of menopause
or anxiety in younger women having to deal with family
and workload have to be considered too. The growing
high-risk demographic of single working mothers would
be a good example, as the prevalence of depression in
this group is significantly higher than in married controls
due to chronically high stress levels (191). Sub-clusters
of patients within the respective RMDs will have to be
carefully distinguished as may have become clear in the
course of this review. Current research that is exploring the
crosstalk between Glucocorticoids, Reproductive Hormones and
Immunity (192) may also benefit from picking up this thread of
research on RMDs.
Ultimately, our review is meant to further establish RMDs
as a phase-sensitive distinct clinical entity warranting the
development of a new diagnostic category on RMDs in future
editions of ICD and DSM. In particular, in the face of the
compelling evidence available on perimenopausal depression, it
is urgently necessary to insert a respective diagnostic category,
as even the upcoming ICD-11 does not make any reference
to this particular RMD. Integrating our knowledge on these
health issues of women in a bigger picture allows us to take a
psychoneuroendocrinologically informed stance on fundamental
societal questions that have long been of pressing relevance.
These include the differential social support and stress profiles
in the context of different depression prevalence between men
and women (120) and involves factors like the increase in stress-
related diseases world-wide.
As we tried to show in this review, the hormonal as
well as the psychosocial environment of the menopause
transition is clearly implicated in the development of for
instance perimenopausal depression. There is mounting evidence
that the presence of psychosocial stress may interact with
this hormonal environment to confer an increased mood
vulnerability. Taking such a psychoneuroendocrinologically
informed stance also calls for new teaching contents in medical
and psychological faculties as well as a new type of practices
for Gynecological Psychoneuroendocrinology (193). In this
new type of practice treatment options will be offered that
integrate neuroendocrinological knowledge with psychiatric,
gynecological, urological, and social evidence as well as the latest
insights of sexual medicine. This new type of practice supports
women in finding adequate solutions to their problems, an
extraordinarily demanding integrative effort of various medical,
social and psychological services that women were left alone
with for most of this world’s medical history. In research,
teaching and practice that takes such a multidisciplinary stance,
a whole array of aspects can be taken into account in finding
health solutions for women. For instance, also the aspects of
pain and inflammation that are linked to depression (194)
has never been elucidated in its link to altered GABAergic
mechanisms found in RMDs. Neuro-orthopedic, gynecological
as well as urological inflammations such as cystitis often
represent masked depressive processes. These are aspects which
would greatly benefit progress on RMDs in research and
practice if addressed in such a multidisciplinary way. On
the basis of a longitudinal, multi-disciplinary perspective on
RMDs that takes psychosocial and neuroendocrine factors into
account, far more effective prevention and intervention strategies
including pharmacological, psychotherapeutic, and psychosocial
approaches may be developed, with the aim to improve mental
health of the many women in this world affected by reproductive
mood disorders.
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